Suppr超能文献

库欣病治疗后获得性催乳素缺乏(APD)是不可逆性严重生长激素缺乏(GHD)的可靠标志物,但不能反映疾病状态。

Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.

作者信息

Mukherjee A, Murray R D, Teasdale G M, Shalet S M

机构信息

Christie Hospital, Manchester, UK.

出版信息

Clin Endocrinol (Oxf). 2004 Apr;60(4):476-83. doi: 10.1111/j.1365-2265.2004.02004.x.

Abstract

OBJECTIVE

We have previously reported that acquired prolactin deficiency (APD) is a marker for severe hypopituitarism and observed a high prevalence of APD in patients treated for Cushing's disease. Recovery of GH secretion is recognized to occur in a proportion of patients treated for Cushing's disease after the effects of glucocorticoid excess on GH secretion have subsided. The aim of this study was to investigate further the association between APD, treated Cushing's disease and, in particular, to determine whether recovery of GH secretion may occur in these patients.

METHODS

Fifty-seven patients (42 female), in remission after treatment for Cushing's disease, were studied. The cohort comprised 13 patients with, and 44 without APD. APD was defined as a serum prolactin persistently below the detection limit of the assay. Severe GH deficiency was defined as a peak GH response of less than 9 mU/l during a GH stimulation test. Age and gender did not significantly differ between subgroups.

RESULTS

Of the 13 patients with APD, a macroadenoma was present in one patient, a microadenoma was present in 10, no lesion was detected in one, and in one patient (treated with an yttrium implant) the size of the tumour was unknown. Of the 28 patients who did not have APD, who were treated with primary surgery a microadenoma was present in 23 and a macroadenoma was present in five. Detailed pituitary imaging was not available in 16 patients who did not have APD, who were treated with primary external XRT. Deficiencies of GH, TSH, LH/FSH (P < 0.0001) and ADH (P = 0.006) status, by conventional testing, were present more frequently in the APD subgroup. In contrast, the prevalence of ACTH deficiency after treatment was not different between the APD and non-APD groups. However, the requirement for additional therapy, targeting the pituitary or adrenal gland, after primary treatment, in those patients not rendered ACTH-deficient, was significantly greater in the APD compared with the non-APD groups (P = 0.003). After pituitary surgery, a significant correlation between peak GH response and interval since remission of Cushing's syndrome was found in the subgroup without APD (r = 0.4, P = 0.04). Four patients who did not have APD, who had documented severe GHD in the immediate postoperative period displayed normalization of GH secretion, when re-tested after a mean interval of 27.2 months. In contrast, no patient with APD after pituitary surgery demonstrated a detectable GH response after up to 132 months of follow-up. No patient with APD showed recovery of prolactin secretion by the time of the most recent measurement (mean 57 months). All 10 patients who developed APD immediately after pituitary surgery had undergone a radical procedure (either a subtotal or total hypophysectomy). In contrast, of 28 patients with Cushing's disease who did not develop APD, only four underwent radical surgery (P < 0.0001). Seven of 14 patients (50%) who underwent a radical operation and two of 20 treated by selective adenomectomy (10%) required additional treatment to achieve control of Cushing's syndrome (P = 0.04).

CONCLUSION

In the presence of APD, patients with Cushing's disease do not experience recovery of GH secretion after treatment, even after the effects of glucocorticoid excess subside. In the absence of APD, GH status may normalize after successful surgical treatment. Although a marker for severe hypopituitarism, APD does not indicate success of treatment of Cushing's disease and may be associated with detectable ACTH secretion from residual corticotroph adenoma activity. APD after pituitary surgery for Cushing's disease occurs only after a radical operation. When a selective adenomectomy is not possible, control of Cushing's disease by operation is less frequent and when achieved, is more often at the cost of hypopituitarism. The optimal management of such patients requires further study.

摘要

目的

我们之前曾报道,获得性催乳素缺乏(APD)是严重垂体功能减退的一个标志,并且在库欣病患者中观察到APD的高患病率。在糖皮质激素过多对生长激素(GH)分泌的影响消退后,一部分接受库欣病治疗的患者的GH分泌会恢复。本研究的目的是进一步探讨APD、接受治疗的库欣病之间的关联,特别是确定这些患者中GH分泌是否会恢复。

方法

研究了57例库欣病治疗后缓解的患者(42例女性)。该队列包括13例有APD的患者和44例无APD的患者。APD定义为血清催乳素持续低于检测限。严重GH缺乏定义为GH刺激试验期间GH峰值反应低于9 mU/l。亚组间年龄和性别无显著差异。

结果

在13例有APD的患者中,1例存在大腺瘤,10例存在微腺瘤,1例未检测到病变,1例(接受钇植入治疗)肿瘤大小未知。在28例无APD且接受一期手术治疗的患者中,23例存在微腺瘤,5例存在大腺瘤。16例无APD且接受一期外照射放疗(XRT)治疗的患者没有详细的垂体影像学资料。通过传统检测,APD亚组中GH、促甲状腺激素(TSH)、促黄体生成素/促卵泡生成素(LH/FSH)(P < 0.0001)和抗利尿激素(ADH)(P = 0.006)缺乏状态更常见。相比之下,治疗后促肾上腺皮质激素(ACTH)缺乏的患病率在APD组和非APD组之间没有差异。然而,在那些未导致ACTH缺乏的患者中,APD组在一期治疗后针对垂体或肾上腺的额外治疗需求显著高于非APD组(P = 0.003)。垂体手术后,在无APD的亚组中发现GH峰值反应与库欣综合征缓解后的间隔时间之间存在显著相关性(r = 0.4,P = 0.04)。4例无APD且术后即刻记录有严重生长激素缺乏症(GHD)的患者,在平均间隔27.2个月后重新检测时,GH分泌恢复正常。相比之下,垂体手术后有APD的患者在长达132个月的随访中均未显示出可检测到的GH反应。到最近一次测量时(平均57个月),没有APD的患者催乳素分泌恢复。垂体手术后立即发生APD的所有10例患者均接受了根治性手术(次全或全垂体切除术)。相比之下,28例未发生APD的库欣病患者中,只有4例接受了根治性手术(P < 0.0001)。接受根治性手术的14例患者中有7例(50%)和接受选择性腺瘤切除术治疗的20例患者中有2例(10%)需要额外治疗以实现库欣综合征的控制(P = 0.04)。

结论

存在APD时,库欣病患者治疗后即使糖皮质激素过多的影响消退,GH分泌也不会恢复。在无APD的情况下,成功手术治疗后GH状态可能恢复正常。虽然APD是严重垂体功能减退的一个标志,但它并不表明库欣病治疗成功,并且可能与残留促肾上腺皮质激素腺瘤活动导致的可检测到的ACTH分泌有关。垂体手术后库欣病的APD仅在根治性手术后发生。当无法进行选择性腺瘤切除术时,通过手术控制库欣病的频率较低,而且即使实现了控制,往往也会以垂体功能减退为代价。对此类患者的最佳管理需要进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验